• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成人 AML 中的移植前流式细胞术微小残留病动力学与预处理强度

Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML.

机构信息

Department of Medicine, Residency Program, University of Washington, Seattle, WA.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

出版信息

Blood. 2022 Mar 17;139(11):1694-1706. doi: 10.1182/blood.2021014804.

DOI:10.1182/blood.2021014804
PMID:34995355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8931514/
Abstract

In acute myeloid leukemia (AML), measurable residual disease (MRD) before or after allogeneic hematopoietic cell transplantation (HCT) is an established independent indicator of poor outcome. To address how peri-HCT MRD dynamics could refine risk assessment across different conditioning intensities, we analyzed 810 adults transplanted in first or second remission after myeloablative conditioning (MAC; n = 515) or non-MAC (n = 295) who underwent multiparameter flow cytometry-based MRD testing before as well as 20 to 40 days after allografting. Patients without pre- and post-HCT MRD (MRDneg/MRDneg) had the lowest risks of relapse and highest relapse-free survival (RFS) and overall survival (OS). Relative to those patients, outcomes for MRDpos/MRDpos and MRDneg/MRDpos patients were poor regardless of conditioning intensity. Outcomes for MRDpos/MRDneg patients were intermediate. Among 161 patients with MRD before HCT, MRD was cleared more commonly with a MAC (85 of 104; 81.7%) than non-MAC (33 of 57; 57.9%) regimen (P = .002). Although non-MAC regimens were less likely to clear MRD, if they did, the impact on outcome was greater. Thus, there was a significant interaction between conditioning intensity and "MRD conversion" for relapse (P = .020), RFS (P = .002), and OS (P = .001). Similar findings were obtained in the subset of 590 patients receiving HLA-matched allografts. C-statistic values were higher (indicating higher predictive accuracy) for peri-HCT MRD dynamics compared with the isolated use of pre-HCT MRD status or post-HCT MRD status for prediction of relapse, RFS, and OS. Across conditioning intensities, peri-HCT MRD dynamics improve risk assessment over isolated pre- or post-HCT MRD assessments in patients with AML.

摘要

在急性髓系白血病 (AML) 中,异体造血细胞移植 (HCT) 前后的可测量残留疾病 (MRD) 是预后不良的独立指标。为了研究移植前 MRD 动力学如何改善不同强度预处理条件下的风险评估,我们分析了 810 例接受清髓性预处理 (MAC;n = 515) 或非清髓性预处理 (n = 295) 后处于缓解期的成人患者,这些患者在移植前及移植后 20 至 40 天接受了基于多参数流式细胞术的 MRD 检测。无移植前和移植后 MRD(MRDneg/MRDneg)的患者复发风险最低,无复发生存率 (RFS) 和总生存率 (OS) 最高。与这些患者相比,MRDpos/MRDpos 和 MRDneg/MRDpos 患者的结局较差,且与预处理强度无关。MRDpos/MRDneg 患者的结局则处于中间水平。在 161 例移植前有 MRD 的患者中,MAC 方案(104 例中有 85 例,81.7%)比非 MAC 方案(57 例中有 33 例,57.9%)更常清除 MRD(P =.002)。尽管非 MAC 方案清除 MRD 的可能性较小,但如果清除了,对结局的影响更大。因此,预处理强度与“MRD 转换”对复发(P =.020)、RFS(P =.002)和 OS(P =.001)的交互作用具有显著意义。在接受 HLA 匹配同种异体移植的 590 例患者亚组中也得到了类似的结果。与孤立使用移植前 MRD 状态或移植后 MRD 状态相比,移植前和移植后 MRD 动力学对预测复发、RFS 和 OS 的 C 统计值更高(提示预测准确性更高)。在不同的预处理强度下,移植前和移植后 MRD 动力学改善了 AML 患者的风险评估,优于孤立使用移植前或移植后 MRD 评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9be/8931514/97b7b2a4cbad/bloodBLD2021014804absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9be/8931514/97b7b2a4cbad/bloodBLD2021014804absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9be/8931514/97b7b2a4cbad/bloodBLD2021014804absf1.jpg

相似文献

1
Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML.成人 AML 中的移植前流式细胞术微小残留病动力学与预处理强度
Blood. 2022 Mar 17;139(11):1694-1706. doi: 10.1182/blood.2021014804.
2
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.可测量残留疾病、调理方案强度和年龄可预测首次缓解的急性髓系白血病患者接受异基因造血细胞移植的结果:欧洲血液和骨髓移植学会急性白血病工作组对 2292 例患者的注册分析。
Am J Hematol. 2018 Sep;93(9):1142-1152. doi: 10.1002/ajh.25211. Epub 2018 Aug 15.
3
The Quantification of Minimal Residual Disease Pre- and Post-Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia.多参数流式细胞术检测儿童急性淋巴细胞白血病未预处理及预处理单倍体相合移植后微小残留病的研究
Cytometry B Clin Cytom. 2020 Jan;98(1):75-87. doi: 10.1002/cyto.b.21840. Epub 2019 Aug 19.
4
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.在首次和第二次完全缓解的 AML 患者中,在清髓性异基因造血细胞移植前进行微小残留病检测的意义。
Blood. 2013 Sep 5;122(10):1813-21. doi: 10.1182/blood-2013-06-506725. Epub 2013 Jul 11.
5
Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.通过多参数流式细胞术对成人急性髓系白血病移植前后可测量的(“最小”)残留病进行定量分析。
Leukemia. 2016 Jul;30(7):1456-64. doi: 10.1038/leu.2016.46. Epub 2016 Feb 29.
6
Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia.成人急性髓系白血病异基因造血细胞移植后残留细胞遗传学异常和流式细胞术可测量残留病对结局的相对影响。
Haematologica. 2023 Feb 1;108(2):420-432. doi: 10.3324/haematol.2022.281585.
7
Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.预处理强度、移植前流式细胞术检测的微小残留病与接受异基因造血细胞移植的成人急性髓系白血病患者的预后
Cancers (Basel). 2020 Aug 19;12(9):2339. doi: 10.3390/cancers12092339.
8
Measurable residual disease as predictor of post-day +100 relapses after allografting in adult AML.可测量残留病作为成人急性髓系白血病同种异体移植后+100天复发的预测指标。
Blood Adv. 2025 Feb 11;9(3):558-570. doi: 10.1182/bloodadvances.2024013214.
9
Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.采用多参数流式细胞术检测,单倍体同种异体移植优于匹配的同胞供体移植,可根除 AML 患者移植前微小残留病:回顾性和前瞻性分析。
J Hematol Oncol. 2017 Jul 4;10(1):134. doi: 10.1186/s13045-017-0502-3.
10
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML.流式细胞术检测 MDS/AML 或 AML 成人患者异基因造血细胞移植前微小残留病的相对预后价值。
Am J Hematol. 2024 May;99(5):862-870. doi: 10.1002/ajh.27259. Epub 2024 Feb 21.

引用本文的文献

1
CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia.成人急性髓系白血病患者接受清髓性 HLA 配型相合外周血造血细胞移植后的 CD34+ 细胞剂量、可测量残留病及预后
Cancers (Basel). 2025 Jul 12;17(14):2323. doi: 10.3390/cancers17142323.
2
Acute Myeloid Leukemia-Use of Measurable Residual Disease to Improve Outcomes.急性髓系白血病——利用可测量残留病改善预后
Adv Exp Med Biol. 2025;1475:129-148. doi: 10.1007/978-3-031-84988-6_7.
3
Combination of disease burden before allogeneic transplantation and early post-transplant minimal residual disease predicts survival in patients with acute myeloid leukemia.

本文引用的文献

1
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.2021 年急性髓系白血病微小残留病更新:来自欧洲白血病网微小残留病工作组的共识文件。
Blood. 2021 Dec 30;138(26):2753-2767. doi: 10.1182/blood.2021013626.
2
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.可测量残留病作为急性髓细胞白血病的生物标志物:理论与实际考虑。
Leukemia. 2021 Jun;35(6):1529-1538. doi: 10.1038/s41375-021-01230-4. Epub 2021 Mar 23.
3
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
异基因移植前的疾病负担与移植后早期微小残留病相结合可预测急性髓系白血病患者的生存情况。
Ann Hematol. 2025 Apr;104(4):2469-2481. doi: 10.1007/s00277-025-06325-x. Epub 2025 Apr 25.
4
Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC).异基因造血细胞移植(allo-HCT)优化的2022年欧洲白血病网络(ELN)风险分类:西班牙造血细胞移植组(GETH-TC)中接受异基因造血细胞移植的急性髓系白血病(AML)患者中不良加风险组的验证
Blood Cancer J. 2025 Mar 21;15(1):42. doi: 10.1038/s41408-025-01223-x.
5
Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given.强化缓解后治疗并不能降低首次缓解的急性髓系白血病患者异基因移植后的复发率,不应给予该治疗。
Leukemia. 2025 May;39(5):1053-1055. doi: 10.1038/s41375-025-02560-3. Epub 2025 Mar 12.
6
Impact of high-sensitivity flow cytometry on peri-transplant minimal residual disease kinetics in acute leukemia.高灵敏度流式细胞术对急性白血病移植围手术期微小残留病动力学的影响
Sci Rep. 2025 Feb 26;15(1):6942. doi: 10.1038/s41598-025-91936-7.
7
Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.可测量残留病在接受异基因造血细胞移植治疗急性髓系白血病患者中的意义
Cells. 2025 Feb 15;14(4):290. doi: 10.3390/cells14040290.
8
Modulators of relapse risk in adults allografted for acute myeloid leukemia in measurable residual disease-positive remission.急性髓系白血病异基因移植后处于微小残留病阳性缓解期的成人复发风险调节剂。
Bone Marrow Transplant. 2025 May;60(5):705-707. doi: 10.1038/s41409-025-02533-1. Epub 2025 Feb 17.
9
Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AML.年龄≥60岁的急性髓系白血病成年患者同种异体移植后年龄、预处理强度与预后的关系。
Bone Marrow Transplant. 2025 Apr;60(4):482-490. doi: 10.1038/s41409-025-02516-2. Epub 2025 Jan 29.
10
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia - the CONS.急性髓系白血病首次复发后不久进行造血细胞移植——CONS研究
Haematologica. 2025 Jan 1;110(1):7-10. doi: 10.3324/haematol.2024.286063.
增强的减低强度方案并不能改善急性髓系白血病患者异基因移植后的结局。
J Clin Oncol. 2021 Mar 1;39(7):768-778. doi: 10.1200/JCO.20.02308. Epub 2020 Dec 29.
4
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.有可测量残留病与急性髓系白血病患者生存结局的关联:系统评价和荟萃分析。
JAMA Oncol. 2020 Dec 1;6(12):1890-1899. doi: 10.1001/jamaoncol.2020.4600.
5
Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.预处理强度、移植前流式细胞术检测的微小残留病与接受异基因造血细胞移植的成人急性髓系白血病患者的预后
Cancers (Basel). 2020 Aug 19;12(9):2339. doi: 10.3390/cancers12092339.
6
Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.急性髓系白血病微小残留病灶检测:与常规方法的差异。
Curr Protoc Cytom. 2020 Jun;93(1):e73. doi: 10.1002/cpcy.73.
7
Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML.单倍体核型急性髓细胞白血病患者异基因造血细胞移植前可测量残留病灶对预后的影响。
Leukemia. 2020 Jun;34(6):1577-1587. doi: 10.1038/s41375-020-0717-0. Epub 2020 Jan 23.
8
Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease.基于全身照射(TBI)和非TBI的清髓性预处理方案用于缓解期急性髓系白血病伴或不伴可测量残留病的比较分析。
Leukemia. 2020 Jun;34(6):1701-1705. doi: 10.1038/s41375-019-0671-x. Epub 2019 Dec 3.
9
Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia.急性髓系白血病患者清髓性异基因造血细胞移植后,可测量残留病(MRD)阴性完全缓解的早期实现作为预后的预测指标
Bone Marrow Transplant. 2020 Mar;55(3):669-672. doi: 10.1038/s41409-019-0739-2. Epub 2019 Nov 4.
10
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.阿伯尔·D·A、奥拉齐·A、哈塞尔简·R等。《世界卫生组织髓系肿瘤和急性白血病分类(2016年修订版)》。《血液》。2016年;127(20):2391 - 2405。
Blood. 2016 Jul 21;128(3):462-463. doi: 10.1182/blood-2016-06-721662.